Completed PHASE1 INTERVENTIONAL 2-arm NCT01355016

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 in Healthy Volunteers

Sponsor: MicroDose Therapeutx, Inc

Conditions Drug Safety Respiratory Syncytial Virus Infections

Interventions MDT-637

Updated 6 times since 2017 Last updated: Apr 10, 2012 Started: Sep 30, 2011 Primary completion: Nov 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Drug Safety and Respiratory Syncytial Virus Infections and is currently completed. MicroDose Therapeutx, Inc leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MicroDose Therapeutx, Inc

Data source: MicroDose Therapeutx, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cypress, United States